Form 4: Ocular Therapeutix CLO Receives Significant Equity Grants

Ocular Therapeutix's Chief Legal Officer, Todd Anderman, was granted 64,900 restricted stock units and 197,650 stock options.

Summary

• Todd Anderman, Chief Legal Officer of Ocular Therapeutix, Inc. (OCUL), was granted 64,900 restricted stock units (RSUs) on January 2, 2026.
• Each RSU represents a right to receive one share of the Corporation's common stock.
• The RSUs will vest over three years, with 1/3 vesting on the one-year anniversary of the grant date and an additional 1/3 vesting at the end of each successive one-year period, subject to continued service.
• Anderman was also granted 197,650 stock options on January 2, 2026, with an exercise price of $11.82 per share.
• These stock options will vest over four years, with 1/48 vesting monthly beginning on the one-month anniversary of the grant date, subject to continued service.
• The options have an expiration date of January 1, 2036.
• Following these transactions, Anderman beneficially owns 152,468 shares of common stock and 197,650 stock options.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally positive for aligning management incentives with shareholder interests and executive retention, indicating stability in leadership.

Positives

• The grant of significant equity awards aligns the Chief Legal Officer's interests with long-term shareholder value.
• Equity grants serve as a strong incentive for executive retention and continued service to the company.
• The vesting schedules encourage sustained performance and commitment from a key executive.

Negatives

• The future exercise of stock options and conversion of RSUs will result in dilution for existing shareholders.
• The grants do not represent an immediate cash inflow for the company.

Risks

• The vesting of both RSUs and stock options is contingent upon the reporting person's continued service to the Corporation; unvested awards would be forfeited upon departure.
• The ultimate value realized from these equity awards is dependent on the future market performance of Ocular Therapeutix's common stock.

Future Outlook

The equity grants, with their multi-year vesting schedules, indicate an expectation of continued long-term service and contribution from the Chief Legal Officer to the Corporation's future success.

Industry Context

Equity-based compensation, including RSUs and stock options with performance-based or time-based vesting, is a standard practice in the biotechnology and pharmaceutical industries. This approach is widely used to attract, retain, and incentivize key executives by aligning their financial interests with the long-term performance and growth of the company.

Comparison to Industry Standards

• The structure of these equity grants, involving both RSUs and stock options with multi-year vesting, is consistent with common executive compensation practices observed across the biotech and pharmaceutical sectors.
• Companies like Biogen, Moderna, and Gilead Sciences frequently utilize similar equity incentive plans to reward and retain their senior leadership, linking executive compensation to shareholder value creation over time.

Corporate Governance

Related Party Transactions

• None disclosed beyond standard executive compensation grants to an officer of the company.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of equity awards, but also benefit from incentivized and retained executive leadership.
• Employees: Reflects standard executive compensation practices within the company, potentially impacting morale and perception of fairness in compensation structures.
• Management: Provides significant long-term incentive and compensation, aligning personal wealth creation with company performance.

Next Steps

• Continued service by Todd Anderman to Ocular Therapeutix, Inc. for the vesting of the granted RSUs and stock options.

Key Dates

Recommendation

This Form 4 details routine executive compensation through equity grants, which aligns management incentives with long-term shareholder value. While positive for retention and commitment, it does not provide new operational or financial performance data to warrant a change in investment thesis based solely on this filing. Therefore, a 'hold' recommendation is appropriate.

Keywords

Ocular Therapeutix, OCUL, Todd Anderman, Chief Legal Officer, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, Form 4